Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
This activity is supported by an educational grant from AstraZeneca.
Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.
At the conclusion of this activity, you should be better prepared to:
Susan M. Domchek, MD
Director, MacDonald Women’s Cancer Risk Evaluation Center
Executive Director, Basser Center for BRCA
Basser Professor in Oncology
Perelman School of Medicine
University of Pennsylvania
Disclosure: Other: Honoraria: AstraZeneca, Clovis Oncology, Bristol-Myers Squibb.
Sara A. Hurvitz, MD
Associate Professor of Medicine, Division of Hematology/Oncology
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica–UCLA Outpatient Hematology/Oncology Practice
David Geffen School of Medicine at UCLA
Santa Monica, CA
Disclosure: Grant Research Support: Amgen, Bayer, BI Pharma, Genentech, GlaxoSmithKline, Lilly, Novartis, Pfizer, Roche, Puma Biotechnology, Merrimack Pharmaceuticals, Medivation, Dignitana, OBI Pharma, BioMarin, Cascadian Therapeutics; Other: Travel Support: Lilly, Novartis, OBI Pharma, Bayer.
Mark E. Robson, MD
Chief, Breast Medicine Service
Attending Physician, Breast Medicine and Clinical Genetics Services
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant Research Support: AstraZeneca, AbbVie, Myriad Genetics, Medivation, Invitae; Consultant: AstraZeneca, McKesson.
Melinda L. Telli, MD
Assistant Professor of Medicine in the Division of Medical Oncology
Stanford University School of Medicine
Disclosure: Consultant: Celldex Therapeutics, G1 Therapeutics, Immunomedics, Merck, Pfizer, PharmaMar, Tesaro.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019